Sotrastaurin
Sotrastaurin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against protein kinase C delta type, protein kinase C theta type, protein kinase C eta type, protein kinase C epsilon type, protein kinase C alpha type, and protein kinase C beta type.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | 2 | 6 | — | — | — | 6 | ||
| Uveal neoplasms | D014604 | EFO_1001230 | 3 | 1 | — | — | — | 3 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 1 | — | — | — | 1 | |
| Prolymphocytic leukemia | D015463 | — | 1 | — | — | — | 1 | ||
| Mantle-cell lymphoma | D020522 | C83.1 | — | 1 | — | — | — | 1 | |
| Reactive arthritis | D016918 | EFO_0007460 | M02.3 | — | 1 | — | — | — | 1 |
| Liver transplantation | D016031 | EFO_0010682 | — | 1 | — | — | — | 1 | |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | 1 | — | — | — | 1 |
| Posterior uveitis | D015866 | EFO_1001119 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SOTRASTAURIN |
| INN | sotrastaurin |
| Description | Sotrastaurin is a member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients. It has a role as an EC 2.7.11.13 (protein kinase C) inhibitor, an immunosuppressive agent and an anticoronaviral agent. It is a N-alkylpiperazine, a N-arylpiperazine, a member of indoles, a member of quinazolines and a member of maleimides. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 425637-18-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL565612 |
| ChEBI ID | 90531 |
| PubChem CID | 10296883 |
| DrugBank | — |
| UNII ID | 7I279E1NZ8 (ChemIDplus, GSRS) |
Target
Agency Approved
PRKCD
PRKCD
PRKCQ
PRKCQ
PRKCH
PRKCH
PRKCE
PRKCE
PRKCA
PRKCA
PRKCB
PRKCB
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 430 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more